Anavex Life Sciences Corp.
AVXL
$4.20
-$0.06-1.41%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -32.42% | 32.42% | 61.17% | -9.46% | 16.78% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -48.79% | -20.19% | 1.81% | 2.18% | 22.20% |
| Operating Income | 48.79% | 20.19% | -1.81% | -2.18% | -22.20% |
| Income Before Tax | 53.24% | 15.43% | -8.42% | -6.16% | -40.47% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 53.09% | 15.43% | -8.42% | -6.16% | -40.47% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 53.09% | 15.43% | -8.42% | -6.16% | -40.47% |
| EBIT | 48.79% | 20.19% | -1.81% | -2.18% | -22.20% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 55.32% | 16.50% | -7.34% | -2.89% | -36.00% |
| Normalized Basic EPS | 55.43% | 16.47% | -7.31% | -3.00% | -35.92% |
| EPS Diluted | 55.32% | 16.50% | -7.34% | -2.89% | -36.00% |
| Normalized Diluted EPS | 55.43% | 16.47% | -7.31% | -3.00% | -35.92% |
| Average Basic Shares Outstanding | 4.98% | 1.30% | 1.00% | 3.16% | 3.32% |
| Average Diluted Shares Outstanding | 4.98% | 1.30% | 1.00% | 3.16% | 3.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |